Document is current
Any future updates will be listed below
-
Authors
Gusdon, Aaron M. http://orcid.org/0000-0002-3350-6601
Thompson, Carol B.
Quirk, Kendel
Mayasi, Yunis M.
Avadhani, Radhika
Awad, Issam A.
Hanley, Daniel F.
Ziai, Wendy C.
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U01 NS062851)
- License Information
-
More Information
Article History
Received: 23 April 2021
Accepted: 22 July 2021
First Online: 21 August 2021
Declarations
:
: The study protocol for the original CLEAR III trial was approved by the appropriate institutional review board at each participating site, and written informed consent was obtained from all patients (or legal representatives/surrogates when applicable).
: Not applicable
: AMG (none), CBT (none), KQ (none), YMM (none), RA (none), and IAA receives funding from the NIH; DFH receives funding from the NIH, Department of Defense, and personal fees from Neurotrope and Portola Pharmaceuticals, outside the submitted work; WZ is supported by the NIH and receives consulting fees from C.R. Bard, Inc., outside of the area of the submitted work.
